Recombinant adeno-associated viruses (rAAVs) have been widely used in gene therapy clinical trials and preclinical investigations. There is a significant need for the improvement of current laboratory protocols for the production of rAAV. In the modified protocol, only the cell culture medium was used for rAAV purification, while the cell culture and rAAV purification methods were modified. The rAAV production yield increased six-fold compared to the standard method, while the recovery rate increased by 42.06% and the rAAV infection efficiency improved by 18.88%. This modified rAAV vector production protocol has the advantages of higher yield, higher recovery rate, and higher infection efficiency. It has been tailored toward the needs of rAAV gene therapy laboratories involved in preclinical trials and can be used for diverse in vitro and in vivo preclinical applications.
All Science Journal Classification (ASJC) codes
- Adeno-associated virus production
- Gene therapy
- Recombinant adeno-associated virus
- Viral vector